CRESCENT BIOPHARMA, INC.

CBIO

Held by 8 specialist biotech funds

High Convergence

8 funds opened new positions. Next phase2 readout (CR-001): Feb 2029. Short interest: 18.5% of float.

BiotechnologyCEO: Joshua T. BrummIPO: 2014Website ↗

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations. The company is headquartered in Waltham, Massachusetts.

CRESCENT BIOPHARMA, INC.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Position Details

Know which insider moves are real

Insider Signals

Also Held by These Funds

Research Links

Related Research